Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 14/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 13/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 13/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503607 | 0.95 | TAS1R3 (0.47) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL2470702 | 0.92 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6740806 | 0.92 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL13447235 | 0.92 | TAS1R3 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL27805263 | 0.92 | TAS1R3 (0.45) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL6578763 | 0.90 | TAS1R3 (0.42) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL19130691 | 0.90 | MEN1 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL2921028 | 0.90 | TAS1R3 (0.38) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL2011531 | 0.90 | MEN1 (0.46) | TAS1R3TAS1R1TAS1R2MEN1KMT2A | |
| SCHEMBL545012 | 0.90 | HCAR2 (0.41) | TAS1R3TAS1R1TAS1R2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1964860-B1 | ETHYLENE POLYMER, CATALYST FOR PRODUCTION OF ETHYLENE POLYMER, AND PROCESS FOR PRODUCTION OF ETHYLENE POLYMER | TOSOH CORP (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9371422-B2 | Titanium containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts | DOW CORNING CORPORATION (US) | 2016-06-21 | — | — | US | disclosed |
| EP-1473323-B1 | Polyethylene composition and process for producing same | TOSOH CORP (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-20160009652-A1 | SMALL-MOLECULE MODULATORS OF MELANIN EXPRESSION | UNIV ROCHESTER (US) | 2016-01-14 | — | — | US | disclosed |
| US-20140213690-A1 | Titanium Containing Complex and Condensation Reaction Catalysts, Methods for Preparing the Catalysts, and Compositions Containing the Catalysts | DOW CORNING CORPORATION (US) | 2014-07-31 | — | — | US | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-7838611-B2 | Ethylene polymer, catalyst for ethylene polymer production, and method for producing ethylene polymer | TOSOH CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7678866-B2 | Polyethylene composition and process for producing same | TOSOH CORPORATION (JP) | 2010-03-16 | — | — | US | disclosed |
| EP-1964860-A1 | ETHYLENE POLYMER, CATALYST FOR PRODUCTION OF ETHYLENE POLYMER, AND PROCESS FOR PRODUCTION OF ETHYLENE POLYMER | Tosoh Corporation (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| WO-2007090748-A1 | BENZAMIDE AND HETEROARENE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1473323-A1 | Polyethylene composition and process for producing same | Tosoh Corporation (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-20040214953-A1 | Polyethylene composition and process for producing same | TOSOH CORPORATION | 2004-10-28 | — | — | US | disclosed |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-07-24 | — | — | US | disclosed |
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | WEICHERT ANDREAS (DE) | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009652-A1 | SMALL-MOLECULE MODULATORS OF MELANIN EXPRESSION | TYR, MITF, MC1R | TAS1R3 2984/4885TAS1R1 3518/4885TAS1R2 2518/4885 |
| US-20020099222-A1 | Heterocyclically substituted benzoylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them | TNNI3, HBG1, TNNT2 | TAS1R3 4127/4885TAS1R1 3012/4885TAS1R2 4057/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TAS1R3 3113/4885TAS1R1 3639/4885TAS1R2 3936/4885 |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | TAS1R3 3709/4885TAS1R1 3365/4885TAS1R2 3415/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | TAS1R3 3113/4885TAS1R1 3639/4885TAS1R2 3936/4885 |
| US-20030139607-A1 | HETEROCYCLICALLY SUBSTITUTED BENZOYLGUANIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS, AND MEDICAMENTS COMPRISING THEM | TNNI3, HBG1, TNNT2 | TAS1R3 4127/4885TAS1R1 3012/4885TAS1R2 4057/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TAS1R3 3113/4885TAS1R1 3639/4885TAS1R2 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.